Hospital
Curry Health District
Curry Health District was paid $13.28M by Medicaid between Jan 2018 and Nov 2024, across 110 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 20% of everything it billed.
33Billing provider infoCURRY HEALTH DISTRICT
GOLD BEACH, OR 97444
GOLD BEACH, OR 97444
33aNPI1487696985assigned 06/11/2006
33bProvider typeCritical Access Hospital
28Total paid$13.28M
24GClaims183,905
24DCodes billed110
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Oregon
Rank by total paid#7 of 22
Median peer was paid$3.52M
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,033 | $1.73M | |
| 2019 | 31,990 | $1.70M | |
| 2020 | 20,338 | $1.39M | |
| 2021 | 28,374 | $2.30M | |
| 2022 | 28,258 | $2.65M | |
| 2023 | 24,367 | $1.96M | |
| 2024incomplete | 17,545 | $1.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 42,119 | 17,237 | $2.65M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 51,278 | 22,314 | $2.59M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 8,170 | 6,985 | $2.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 1,815 | 1,429 | $1.08M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.1% | 5,119 | 4,508 | $949K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 847 | 698 | $361K |
| 80053 | Comprehensive metabolic panel | 2.6% | 9,758 | 7,889 | $351K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.0% | 1,036 | 317 | $267K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.9% | 3,068 | 1,289 | $257K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 10,066 | 8,124 | $229K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 5,441 | 2,408 | $214K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 1,384 | 297 | $184K |
98 more codes
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.2% | 1,653 | $158K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.2% | 284 | $155K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 10,724 | $146K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 493 | $109K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,273 | $106K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,482 | $86K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 706 | $83K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 477 | $72K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 654 | $69K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 679 | $61K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,960 | $52K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 471 | $48K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 179 | $48K |
| 81001 | <1% | 2,286 | $47K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 474 | $43K |
| 90837 | Psychotherapy session, about an hour | <1% | 237 | $39K |
| 80061 | Lipid panel | <1% | 1,002 | $38K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 435 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 728 | $33K |
| 86710 | <1% | 1,404 | $31K | |
| 71045 | Radiologic examination, chest; single view | <1% | 457 | $31K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 465 | $22K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 615 | $22K |
| 83605 | <1% | 603 | $21K | |
| 84484 | <1% | 513 | $21K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 18 | $19K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 296 | $17K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 238 | $16K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 14 | $15K |
| 99156 | <1% | 138 | $15K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 539 | $14K |
| 0012A | <1% | 815 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 548 | $13K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 52 | $12K |
| 0011A | <1% | 761 | $11K | |
| 11721 | <1% | 1,195 | $11K | |
| 85730 | <1% | 609 | $11K | |
| 90686 | <1% | 513 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 880 | $10K |
| 82553 | <1% | 351 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 201 | $10K |
| 81003 | <1% | 411 | $9K | |
| 90670 | <1% | 308 | $9K | |
| 73630 | <1% | 85 | $8K | |
| 85610 | <1% | 611 | $8K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 21 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 159 | $8K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 161 | $7K |
| 87631 | <1% | 14 | $6K | |
| 90698 | <1% | 287 | $6K | |
| 82550 | <1% | 374 | $6K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 57 | $6K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 51 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 211 | $5K |
| 0013A | <1% | 437 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $5K |
| 96127 | <1% | 130 | $5K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 240 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 79 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 60 | $4K |
| J3490 | Unclassified drugs | <1% | 160 | $4K |
| 83735 | <1% | 180 | $4K | |
| 94060 | <1% | 14 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 213 | $3K |
| 90685 | <1% | 167 | $3K | |
| 84439 | <1% | 114 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 120 | $3K |
| 81025 | <1% | 89 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 64 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 85 | $2K |
| 94729 | <1% | 14 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 82 | $2K |
| 99406 | <1% | 136 | $2K | |
| 94726 | <1% | 14 | $2K | |
| 90744 | <1% | 91 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 12 | $2K |
| 0064A | <1% | 124 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 296 | $1K |
| 90710 | <1% | 39 | $1K | |
| 0134A | <1% | 115 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 49 | $1K |
| 96158 | <1% | 25 | $1K | |
| 83690 | <1% | 77 | $1K | |
| 90680 | <1% | 44 | $1K | |
| 86140 | <1% | 69 | $858.00 | |
| 99442 | <1% | 15 | $730.75 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 20 | $587.50 |
| 99417 | Prolong home eval add 15m | <1% | 24 | $551.20 |
| 90633 | <1% | 32 | $502.37 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 29 | $429.70 |
| 82150 | <1% | 14 | $397.62 | |
| 90648 | <1% | 17 | $344.32 | |
| 84100 | <1% | 25 | $314.40 | |
| 90700 | <1% | 15 | $300.40 | |
| 98926 | <1% | 16 | $257.52 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 22 | $240.52 |
| G0008 | Administration of influenza virus vaccine | <1% | 37 | $162.40 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, VIRGINIA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Curry Health District | Port Orford, OR | $157K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.